team-young-specialist-doctors-standing-corridor-hospital.jpg

PRESS RELEASES

abstract-luxury-gold-yellow-gradient-studio-wall-well-use-as-backgroundlayoutbanner-produc

In December 2025, our Founder and Medical Director, Dr. Shishuka Malhotra, and our organization Neuro-Behavioral Clinical Research (NBR) were featured in International Business Times. A meaningful and well-deserved recognition!

The article not only highlights NBR's impactful research efforts, but also shines a light on our nonprofit initiative, Ohio Center for Hope (OCH). Designed to complement NBR's clinical research, OCH provides care for individuals who may not qualify for trials, ensuring no one is left without support.

Although we’re sharing this news in February 2026, the pride we feel in Dr. Malhotra's leadership and the work being done across both NBR and OCH is just as strong. Please join us in congratulating Dr. Shishuka Malhotra on this outstanding achievement and continued commitment to compassionate, inclusive care.

Read Full Article

ALZHEIMER'S STUDY

Alzheimer’s study seeks participants, aims to slow progression of disease.

Read this story:

Read All

MDD TRIAL RESULTS

NBClinic participated in the Phase 2 clinical trial evaluating Neurocrine’s NBI‑1065845, showing promising results in MDD.

Read this study:

Read All

young-handsome-casual-african-american-man-looking-camera-coffee-break-with-friend-modern-

MDD TRIAL POSITIVE

NBClinic was a participating site in the Phase 3 clinical trial demonstrating positive results for zuranolone in major depressive disorder.

Read this study:

Read All

WORK BEING DONE AT NBR

Dr. Malhotra discusses the work being done at Neuro-Behavioral Clinical Research.

Watch the Video | Read this story:

Read All

female-patient-being-reassured-by-doctor-hospital-room.jpg

BIPOLAR STUDY EFFECTIVE

NBClinic actively participated in the Phase III clinical trials evaluating Fanapt’s efficacy for bipolar disorder.

Read this study:

Read All

ADHD TREATMENT

NBClinic contributed as a clinical trial site in studies leading to the FDA approval of Qelbree for ADHD treatment.

Read this study:

Read All

PSILOCYBIN TREATMENT

NBClinic was a clinical trial site for Compass Pathways’ Phase 3 study of COMP360 psilocybin for treatment-resistant depression.

Read this study:

Read All

SCHIZOPHRENIA DATA

NBClinic served as a clinical trial site for the Phase 3 study of KarXT in schizophrenia, whose results were presented at ECNP.

Read this story:

Read All

TONMYA FDA APPROVAL

NBClinic participated in the clinical trial leading to the FDA approval of Tonmya™ for fibromyalgia treatment.

Read this study:

Read All

NEURO-BEHAVIORAL CLINICAL RESEARCH

PRESS RELEASES

CONTACT

HOURS